The Division of Rheumatology strives to understand more about scleroderma and systemic sclerosis through research. Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease.
Study Name/IRB#/PI | Brief Description | Basic Eligibility Criteria | Contact |
MINERAL; Microbiome and Neutrophil associated factors in Rheumatoid Arthritis and Autoimmune-related Interstitial Lung Disease 20-2769 Melissa Griffith, MD | An observational study to investigate the causes of chronic lung disease in rheumatoid arthritis and other autoimmune diseases | 1. At least 18 years old 2. Falls under one of the following criteria: a. Diagnosis of scleroderma b. Diagnosis of idiopathic pulmonary fibrosis (IPF) or interstitial pneumonia with autoimmune features (IPAF) c. Diagnosis of RA with associated interstitial lung disease d. Diagnosis of RA with previous lung abnormalities seen on lung scan | RAStudies@cuanschutz.edu, 303-724-0071
|
CAR-T study in SLE, IIM and SSc 24-0289 Melissa Griffith, MD | A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants with Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, idiopathic Inflammatory Myopathy or Systemic Sclerosis |
| Chong Pedrick 303-724-7518
Najeeb Arishi 303-724-7512
Mario Farag 303-724-6438 Mario.Farag@cuanschutz.edu |
Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length. A visit to determine an individuals eligibility may be required. A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.